ArticleAntimicrobial agents and chemotherapy2013
Introduction of a lysine residue promotes aggregation of temporin L in lipopolysaccharides and augmentation of its antiendotoxin property.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- Chemical Optimization of Temporin A-L Peptides: From Native Isoforms to Enhanced Antimicrobial Analogs.ChemMedChem · 2026Review
- Synthesis of Temporin-SHa Retro Analogs with Lysine Addition/Substitution and Antibiotic Conjugation to Enhance Antibacterial, Antifungal, and Anticancer Activities.Antibiotics (Basel, Switzerland) · 2024Article
- Dual functional therapeutics: mitigating bacterial infection and associated inflammation.RSC medicinal chemistry · 2023Review
- Evaluation of the Synthetic Multifunctional Peptide Hp-MAP3 Derivative of Temporin-PTa.Toxins · 2023Article
- Temporin B Forms Hetero-Oligomers with Temporin L, Modifies Its Membrane Activity, and Increases the Cooperativity of Its Antibacterial Pharmacodynamic Profile.Biochemistry · 2022Article
- First-in-Class Cyclic Temporin L Analogue: Design, Synthesis, and Antimicrobial Assessment.Journal of medicinal chemistry · 2021Article
- Aggregation and Its Influence on the Bioactivities of a Novel Antimicrobial Peptide, Temporin-PF, and Its Analogues.International journal of molecular sciences · 2021Article
- SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity.Journal of molecular cell biology · 2020Article
- Antimicrobial Peptides with Enhanced Salt Resistance and Antiendotoxin Properties.International journal of molecular sciences · 2020Article
- Design, Engineering and Discovery of Novel α-Helical and β-Boomerang Antimicrobial Peptides against Drug Resistant Bacteria.International journal of molecular sciences · 2020Review
- Antimicrobial Peptides Display Strong Synergy with Vancomycin Against Vancomycin-ResistantInternational journal of molecular sciences · 2020Article
- Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.Frontiers in cellular and infection microbiology · 2020Review
- Immunomodulatory Functions of the Human Cathelicidin LL-37 (aa 13-31)-Derived Peptides are Associated with Predicted α-Helical Propensity and Hydrophobic Index.Biomolecules · 2019Article
- Temporin L and aurein 2.5 have identical conformations but subtly distinct membrane and antibacterial activities.Scientific reports · 2019Article
- A collagen domain-derived short adiponectin peptide activates APPL1 and AMPK signaling pathways and improves glucose and fatty acid metabolisms.The Journal of biological chemistry · 2018Article
- Recent Advances in Antibacterial and Antiendotoxic Peptides or Proteins from Marine Resources.Marine drugs · 2018Review
- Hybridization and antibiotic synergism as a tool for reducing the cytotoxicity of antimicrobial peptides.Infection and drug resistance · 2018Article
- Arminin 1a-C, a novel antimicrobial peptide from ancient metazoanDrug design, development and therapy · 2018Article
- A short D-enantiomeric antimicrobial peptide with potent immunomodulatory and antibiofilm activity against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.Scientific reports · 2017Article
- Molecular Dynamics Simulations of the Host Defense Peptide Temporin L and Its Q3K Derivative: An Atomic Level View from Aggregation in Water to Bilayer Perturbation.Molecules (Basel, Switzerland) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temporin L (TempL) is a 13-residue frog antimicrobial peptide that shows moderate bactericidal activity and antiendotoxin properties in macrophages. We envisioned that, due to its very hydrophobic nature, the peptide might fail to show its desired biological properties. It was predicted by employing the available algorithms that the replacement of a glutamine by lysine at position 3 could appreciably reduce its aggregation propensity in an aqueous environment. In order to investigate the structural, functional, and biological consequences of replacement of glutamine by lysine at its third position, TempL and the corresponding analog, Q3K-TempL, was synthesized and characterized. Introduction of the lysine residue significantly promoted the self-assembly and oligomeric state of TempL in lipopolysaccharide (LPS). Q3K-TempL exhibited augmented binding to LPS and also dissociated LPS aggregates with greater efficacy than TempL. Further, Q3K-TempL inhibited the LPS-induced proinflammatory cytokines in rat primary macrophages in vitro and in vivo in BALB/c mice with greater efficacy than TempL. The results showed that a simple amino acid substitution in a short hydrophobic antimicrobial peptide, TempL, enhanced its antiendotoxin properties and illustrate a plausible correlation between its aggregation properties in LPS and LPS detoxification activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.